Ironwood Pharmaceuticals, Inc.
General ticker "IRWD" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $563.8M (TTM average)
Ironwood Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 32.2%.
Estimated limits based on current volatility of 3.4%: low 3.57$, high 3.82$
Factors to consider:
- Total employees count: 100 (-60.5%) as of 2025
- North America accounted for 97.7% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Operational and conduct risks, Market competition, Regulatory and compliance, Manufacturing capacity, Capital funding
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.81$, 5.97$]
- 2026-12-31 to 2027-12-31 estimated range: [2.72$, 5.58$]
Financial Metrics affecting the IRWD estimates:
- Positive: with PPE of 23.3 at the end of fiscal year the price was low
- Positive: 22.58 < Operating profit margin, % of 33.26
- Positive: 15.29 < Operating cash flow per share per price, % of 24.03
- Positive: Industry inventory ratio change (median), % of -0.31 <= 0
- Positive: 5.14 < Return on assets ratio (scaled to [-100,100]) of 5.71
- Positive: -0.14 < Investing cash flow per share per price, % of -0.01
- Positive: -51.61 < Industry operating profit margin (median), % of -17.91
- Positive: Shareholder equity ratio, % of -65.97 <= 7.04
Short-term IRWD quotes
Long-term IRWD plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $442.74MM | $351.41MM | $296.15MM |
| Operating Expenses | $1,388.16MM | $258.29MM | $197.65MM |
| Operating Income | $-945.43MM | $93.12MM | $98.50MM |
| Non-Operating Income | $-2.64MM | $-27.93MM | $-28.48MM |
| Interest Expense | $21.63MM | $33.03MM | $32.75MM |
| R&D Expense | $116.08MM | $111.42MM | $95.14MM |
| Income(Loss) | $-948.07MM | $65.20MM | $70.03MM |
| Taxes | $83.49MM | $64.32MM | $46.01MM |
| Net Income(Loss)* | $-1,002.24MM | $0.88MM | $24.02MM |
| Stockholders Equity | $-346.30MM | $-301.33MM | $-261.83MM |
| Assets | $471.07MM | $350.91MM | $396.90MM |
| Operating Cash Flow | $183.43MM | $103.55MM | $127.04MM |
| Capital expenditure | $0.27MM | $0.14MM | $0.03MM |
| Investing Cash Flow | $-1,026.32MM | $-0.14MM | $-0.03MM |
| Financing Cash Flow | $277.16MM | $-106.97MM | $0.22MM |
| Earnings Per Share** | $-6.45 | $0.01 | $0.15 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.